Teladoc Health, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87918A1051
USD
7.78
0.25 (3.32%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

5.0 M

Shareholding (Mar 2025)

FII

20.52%

Held by 217 FIIs

DII

43.09%

Held by 53 DIIs

Promoter

0.14%

How big is Teladoc Health, Inc.?

22-Jun-2025

As of Jun 18, Teladoc Health, Inc. has a market capitalization of 1,242.08 million, with net sales of 2,552.81 million and a net profit of -1,012.37 million over the latest four quarters. The company reported shareholder's funds of 1,491.08 million and total assets of 3,763.36 million as of Dec 24.

Market Cap: As of Jun 18, Teladoc Health, Inc. has a market capitalization of 1,242.08 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Teladoc Health, Inc. reported net sales of 2,552.81 million and a net profit of -1,012.37 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,491.08 million and total assets of 3,763.36 million.

Read More

What does Teladoc Health, Inc. do?

22-Jun-2025

Teladoc Health, Inc. offers virtual healthcare services and is classified as a small-cap company with a market cap of approximately $1.24 billion. As of March 2025, it reported net sales of $629 million and a net loss of $93 million.

Overview: <BR>Teladoc Health, Inc. provides virtual healthcare services and operates within the Pharmaceuticals & Biotechnology industry, classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 629 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -93 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,242.08 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.25 <BR>Return on Equity: -10.14% <BR>Price to Book: 0.87<BR><BR>Contact Details: <BR>Address: 2 Manhattanville Rd Ste 203, PURCHASE NY: 10577-2118 <BR>Tel: 1 203 6352002 <BR>Website: https://teladochealth.com/

Read More

Who are in the management team of Teladoc Health, Inc.?

22-Jun-2025

As of March 2022, the management team of Teladoc Health, Inc. includes David Snow (Independent Chairman), Jason Gorevic (CEO), and directors Christopher Bischoff, Karen Daniel, Sandra Fenwick, Hemant Taneja, and Glen Tullman, who oversee the company's strategic direction and operations.

As of March 2022, the management team of Teladoc Health, Inc. includes the following individuals:<BR><BR>- Mr. David Snow, Independent Chairman of the Board<BR>- Mr. Jason Gorevic, Chief Executive Officer and Director<BR>- Mr. Christopher Bischoff, Director<BR>- Ms. Karen Daniel, Director<BR>- Ms. Sandra Fenwick, Director<BR>- Mr. Hemant Taneja, Director<BR>- Mr. Glen Tullman, Director<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.

Read More

Is Teladoc Health, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Teladoc Health, Inc. shows a mildly bullish technical trend supported by weekly and monthly indicators, but caution is advised due to mixed signals and poor long-term performance.

As of 3 October 2025, the technical trend for Teladoc Health, Inc. has changed from sideways to mildly bullish. The weekly and monthly MACD indicators are both mildly bullish, supporting this stance. The KST, Dow Theory, and OBV also indicate a mildly bullish outlook on a weekly and monthly basis. However, the daily moving averages are mildly bearish, which presents some caution. The Bollinger Bands show a bullish signal on the weekly but a mildly bearish signal on the monthly.<BR><BR>In terms of performance, Teladoc has outperformed the S&P 500 over the past week and month, with returns of 4.51% and 9.59% compared to the S&P's 1.09% and 4.15%, respectively. However, the longer-term returns are significantly negative, with a year-to-date return of -5.72% versus the S&P's 14.18%, and a three-year return of -68.03% compared to the S&P's 82.57%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from different indicators and poor long-term performance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Jun 25

  • DEBTORS TURNOVER RATIO(HY) Lowest at 10.96 times
2

Risky - Negative Operating Profits

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,385 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.23

stock-summary
Return on Equity

-8.67%

stock-summary
Price to Book

0.97

Revenue and Profits:
Net Sales:
632 Million
(Quarterly Results - Jun 2025)
Net Profit:
-33 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.97%
0%
1.97%
6 Months
9.27%
0%
9.27%
1 Year
-29.4%
0%
-29.4%
2 Years
-59.12%
0%
-59.12%
3 Years
-73.36%
0%
-73.36%
4 Years
-91.58%
0%
-91.58%
5 Years
-96.18%
0%
-96.18%

Teladoc Health, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
28.83%
EBIT Growth (5y)
-219.83%
EBIT to Interest (avg)
-13.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.25
Sales to Capital Employed (avg)
0.78
Tax Ratio
1.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
96.77%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.89
EV to EBIT
-8.76
EV to EBITDA
8.80
EV to Capital Employed
0.92
EV to Sales
0.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-10.45%
ROE (Latest)
-10.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 71 Schemes (36.25%)

Foreign Institutions

Held by 217 Foreign Institutions (20.52%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -1.63% vs -1.53% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 96.10% vs -1,184.82% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "631.90",
          "val2": "642.40",
          "chgp": "-1.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "48.90",
          "val2": "49.70",
          "chgp": "-1.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.50",
          "val2": "5.60",
          "chgp": "-19.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.30",
          "val2": "-792.00",
          "chgp": "98.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.70",
          "val2": "-837.70",
          "chgp": "96.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-72.90%",
          "val2": "-76.60%",
          "chgp": "0.37%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1.26% vs 8.13% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -354.26% vs 98.39% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,569.60",
          "val2": "2,602.40",
          "chgp": "-1.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "174.10",
          "val2": "140.80",
          "chgp": "23.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "23.80",
          "val2": "22.30",
          "chgp": "6.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-812.10",
          "val2": "-38.10",
          "chgp": "-2,031.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,001.20",
          "val2": "-220.40",
          "chgp": "-354.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-81.30%",
          "val2": "-80.90%",
          "chgp": "-0.04%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
631.90
642.40
-1.63%
Operating Profit (PBDIT) excl Other Income
48.90
49.70
-1.61%
Interest
4.50
5.60
-19.64%
Exceptional Items
-8.30
-792.00
98.95%
Consolidate Net Profit
-32.70
-837.70
96.10%
Operating Profit Margin (Excl OI)
-72.90%
-76.60%
0.37%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -1.63% vs -1.53% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 96.10% vs -1,184.82% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,569.60
2,602.40
-1.26%
Operating Profit (PBDIT) excl Other Income
174.10
140.80
23.65%
Interest
23.80
22.30
6.73%
Exceptional Items
-812.10
-38.10
-2,031.50%
Consolidate Net Profit
-1,001.20
-220.40
-354.26%
Operating Profit Margin (Excl OI)
-81.30%
-80.90%
-0.04%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -1.26% vs 8.13% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -354.26% vs 98.39% in Dec 2023

stock-summaryCompany CV
About Teladoc Health, Inc. stock-summary
stock-summary
Teladoc Health, Inc.
Pharmaceuticals & Biotechnology
Teladoc Health, Inc. provides virtual healthcare services. The Company provides virtual access to care with a portfolio of services and solutions, which includes various medical subspecialties from non-urgent, episodic needs, such as flu and upper respiratory infections, to chronic, complicated medical conditions, such as cancer and congestive heart failure. It provides virtual healthcare services on a business-to-business (B2B) basis to its clients and provides services to consumers directly and through channel partners. The Company’s consumer brands, including Teladoc, Advance Medical, Best Doctors, BetterHelp and HealthiestYou, provides access to advice and resolution to a range of healthcare needs. Its technology enables consumers to manage their own electronic medical records. It also provides access to a message center, provider finder, image upload capability and enable real-time sharing capabilities with providers that includes visit scheduling.
Company Coordinates stock-summary
Company Details
2 Manhattanville Rd Ste 203 , PURCHASE NY : 10577-2118
stock-summary
Tel: 1 203 6352002
stock-summary
Registrar Details